TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET 24
1.4 CURRENCY AND PRICING 26
1.5 LIMITATIONS 26
1.6 MARKETS COVERED 26
2 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 29
2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 DBMR TRIPOD DATA VALIDATION MODEL 32
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.6 MULTIVARIATE MODELLING 36
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 36
2.8 DBMR MARKET POSITION GRID 37
2.9 VENDOR SHARE ANALYSIS 39
2.10 MARKET END USER COVERAGE GRID 40
2.11 SECONDARY SOURCES 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 44
4.1 PESTEL ANALYSIS 45
4.2 PORTERS FIVE FORCES 46
5 EPIDEMIOLOGY 47
6 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT 48
7 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS 49
7.1 REGULATORY SCENARIO IN THE U.S 49
7.2 REGULATORY SCENARIO IN AUSTRALIA 50
7.3 REGULATORY SCENARIO IN JAPAN 50
7.4 REGULATORY SCENARIO IN CHINA 50
8 MARKET OVERVIEW 52
8.1 DRIVERS 54
8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE 54
8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER 54
8.1.3 IMPROVED IMAGING TECHNIQUES 55
8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS 55
8.2 RESTRAINTS 56
8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER 56
8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES 56
8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS 57
8.3 OPPORTUNITIES 57
8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS 57
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC 57
8.3.3 RISING HEALTHCARE EXPENDITURE 58
8.4 CHALLENGES 59
8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS 59
8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 59
9 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE 60
9.1 OVERVIEW 61
9.2 IMAGING TEST 64
9.2.1 CT SCAN 65
9.2.2 MRI 65
9.2.3 PET 65
9.2.4 OTHERS 65
9.3 MOLECULAR TESTING 66
9.4 ELECTROENCEPHALOGRAPHY (EEG) 66
9.5 LUMBAR PUNCTURE 67
9.6 BIOPSY 68
9.6.1 OPEN BIOPSY 69
9.6.2 STEREOTACTIC BIOPSY 69
9.6.3 NEEDLE BIOPSY 69
9.6.4 NEUROENDOSCOPY 69
9.7 OTHERS 69
10 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE 70
10.1 OVERVIEW 71
10.2 GLIOBLASTOMA MULTIFORME 74
10.3 MENINGIOMAS 75
10.4 ASTROCYTOMAS 76
10.5 ACOUSTIC NEUROMA 77
10.6 OLIGODENDROGLIOMA 78
10.7 OLIGODENDROGLIOMA 78
10.8 OTHERS 79
11 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP 80
11.1 OVERVIEW 81
11.2 35-65 84
11.3 65 AND ABOVE 85
11.4 BELOW 21 86
11.5 21-34 87
12 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER 88
12.1 OVERVIEW 89
12.2 HOSPITALS 92
12.3 SPECIALTY CLINICS 93
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES 94
12.5 AMBULATORY SURGICAL CENTERS 95
12.6 OTHERS 96
13 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY REGION 97
13.1 NORTH AMERICA 98
13.1.1 U.S. 105
13.1.2 CANADA 107
13.1.3 MEXICO 109
14 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE 111
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 111
15 SWOT ANALYSIS 112
16 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE 113
16.1 KONINKLIJKE PHILIPS N.V. 113
16.1.1 COMPANY SNAPSHOT 113
16.1.2 REVENUE ANALYSIS 113
16.1.3 COMPANY SHARE ANALYSIS 114
16.1.4 PRODUCT PORTFOLIO 114
16.1.5 RECENT DEVELOPMENTS 115
16.2 CANON INC. 116
16.2.1 COMPANY SNAPSHOT 116
16.2.2 REVENUE ANALYSIS 116
16.2.3 COMPANY SHARE ANALYSIS 117
16.2.4 PRODUCT PORTFOLIO 117
16.2.5 RECENT DEVELOPMENT 117
16.3 SIEMENS HEALTHCARE GMBH 118
16.3.1 COMPANY SNAPSHOT 118
16.3.2 REVENUE ANALYSIS 119
16.3.3 COMPANY SHARE ANALYSIS 119
16.3.4 PRODUCT PORTFOLIO 120
16.3.5 RECENT DEVELOPMENTS 120
16.4 BD 121
16.4.1 COMPANY SNAPSHOT 121
16.4.2 REVENUE ANALYSIS 122
16.4.3 COMPANY SHARE ANALYSIS 122
16.4.4 PRODUCT PORTFOLIO 123
16.4.5 RECENT DEVELOPMENTS 123
16.5 NIHON KOHDEN CORPORATION. 124
16.5.1 COMPANY SNAPSHOT 124
16.5.2 RECENT FINANCIALS 124
16.5.3 COMPANY SHARE ANALYSIS 125
16.5.4 PRODUCT PORTFOLIO 125
16.5.5 RECENT DEVELOPMENT 125
16.6 BIOCEPT, INC. 126
16.6.1 COMPANY SNAPSHOT 126
16.6.2 REVENUE ANALYSIS 126
16.6.3 PRODUCT PORTFOLIO 127
16.6.4 RECENT DEVELOPMENT 127
16.7 BIOMIND 128
16.7.1 COMPANY SNAPSHOT 128
16.7.2 PRODUCT PORTFOLIO 128
16.7.3 RECENT DEVELOPMENT 128
16.8 CEREBRAL DIAGNOSTIC 129
16.8.1 COMPANY SNAPSHOT 129
16.8.2 PRODUCT PORTFOLIO 129
16.8.3 RECENT DEVELOPMENT 129
16.9 DXCOVER LIMITED 130
16.9.1 COMPANY SNAPSHOT 130
16.9.2 PRODUCT PORTFOLIO 130
16.9.3 RECENT DEVELOPMENT 130
16.10 FONAR CORP. 131
16.10.1 COMPANY SNAPSHOT 131
16.10.2 REVENUE ANALYSIS 131
16.10.3 PRODUCT PORTFOLIO 132
16.10.4 RECENT DEVELOPMENT 132
16.11 FUJIFILM CORPORATION 133
16.11.1 COMPANY SNAPSHOT 133
16.11.2 REVENUE ANALYSIS 133
16.11.3 PRODUCT PORTFOLIO 134
16.11.4 RECENT DEVELOPMENT 134
16.12 GE HEALTHCARE. 135
16.12.1 COMPANY SNAPSHOT 135
16.12.2 REVENUE ANALYSIS 135
16.12.3 PRODUCT PORTFOLIO 136
16.12.4 RECENT DEVELOPMENT 136
16.13 HITACHI, LTD. 137
16.13.1 COMPANY SNAPSHOT 137
16.13.2 REVENUE ANALYSIS 137
16.13.3 PRODUCT PORTFOLIO 138
16.13.4 RECENT DEVELOPMENT 138
16.14 MINFOUND MEDICAL SYSTEMS CO., 139
16.14.1 COMPANY SNAPSHOT 139
16.14.2 PRODUCT PORTFOLIO 139
16.14.3 RECENT DEVELOPMENT 139
16.15 NANTOMICS. 140
16.15.1 COMPANY SNAPSHOT 140
16.15.2 PRODUCT PORTFOLIO 140
16.15.3 RECENT DEVELOPMENT 140
16.16 NEUSOFT CORPORATION 141
16.16.1 COMPANY SNAPSHOT 141
16.16.2 REVENUE ANALYSIS 141
16.16.3 PRODUCT PORTFOLIO 142
16.16.4 RECENT DEVELOPMENT 142
16.17 SEQUOIA HEALTHCARE. 143
16.17.1 COMPANY SNAPSHOT 143
16.17.2 PRODUCT PORTFOLIO 143
16.17.3 RECENT DEVELOPMENT 143
16.18 STERNMED GMBH 144
16.18.1 COMPANY SNAPSHOT 144
16.18.2 PRODUCT PORTFOLIO 144
16.18.3 RECENT DEVELOPMENT 144
16.19 THERMO FISHER SCIENTIFIC INC. 145
16.19.1 COMPANY SNAPSHOT 145
16.19.2 REVENUE ANALYSIS 145
16.19.3 PRODUCT PORTFOLIO 146
16.19.4 RECENT DEVELOPMENT 146
16.20 TIME MEDICAL HOLDING. 147
16.20.1 COMPANY SNAPSHOT 147
16.20.2 PRODUCT PORTFOLIO 147
16.20.3 RECENT DEVELOPMENTS 147
17 QUESTIONNAIRE 148
18 RELATED REPORTS 151

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.